EW FEATURE
114
Controversies in cataract surgery • April 2017
AT A GLANCE
• The application of an antibiotic/
corticosteroid combination into
either the vitreous body or the
anterior chamber after cataract
surgery has shown decided
advantages for patients over
topical application.
• Once you learn the technique,
transzonular drug application is safe.
• TriMoxi is extremely effective in the
prevention of inflammation, CME,
and endophthalmitis following
cataract surgery.
• Intracameral drug application using
dexamethasone and moxifloxacin
is safe and effective and allows the
surgeon to assess a patient's vision
right after surgery.
• There is no learning curve using
intracameral drugs and they offer a
superior method of endophthalmitis
prophylaxis.
• It's not recommended to use TriMoxi
in the anterior chamber.
by Stefanie Petrou Binder, MD, EyeWorld Contributing Writer
Experts discuss the pros
and cons of "dropless"
cataract surgery
Going dropless
Transzonular TriMoxi injection
Zonules after Trimoxi injection
Source (all): G. Auffarth, MD
I
f it's not broken, why fix it?
But when the advantages of the
new override the tried and true,
we pay attention. The applica-
tion of an antibiotic/corticoste-
roid combination into the vitreous
body or the anterior chamber after
cataract surgery has shown decided
advantages for patients in the post-
operative period, including warding
off infection, inflammatory control,
patient convenience, and guaran-
teed compliance, not to mention
appreciably lower costs. Stewart
Galloway, MD, Cumberland Eye
Care, Crossville, Tennessee, and
